What Wegovy actually does to your body — and what it doesn't

The biggest myth: Wegovy makes your body burn fat faster

Most people who ask about Wegovy and the body assume it works like a stimulant, accelerating metabolism, forcing fat cells to release energy, or otherwise speeding something up. That's not what happens. Wegovy's mechanism runs in the opposite direction: it slows things down in a very deliberate, hormone-led way.

Semaglutide, the medicine in Wegovy, is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It signals the pancreas to release insulin, tells the liver to ease off glucose production, and (critically) sends satiety messages to the hypothalamus, the part of the brain that governs hunger. Semaglutide mimics that signal and prolongs it far beyond what a normal meal would produce.

It also slows gastric emptying: food leaves your stomach more gradually, so the physical sense of fullness lasts longer. The result is that most people find they are genuinely less hungry, not fighting hunger with effort. That distinction matters. The weight loss seen with Wegovy isn't explained by willpower. It's explained by a sustained change in appetite physiology, something the NHS medicines information for semaglutide describes straightforwardly: it reduces appetite and how much you eat.

Correcting this myth first matters because it changes what questions you should actually ask: not "does it work" but "does it suit my health picture", and that's a clinical conversation.

What Wegovy does in the body, step by step

A question our prescribers hear most weeks is some version of: "once I inject it, what actually happens?" Here's the honest, factual sequence.

Wegovy is injected subcutaneously once a week, under the skin of the abdomen, thigh or upper arm. From there, semaglutide is absorbed gradually into the bloodstream, reaching peak plasma concentration over roughly one to three days. Because it's a large molecule engineered to resist the enzymes that would normally break GLP-1 down within minutes, it stays active throughout the week.

Circulating semaglutide binds to GLP-1 receptors throughout the body. In the pancreas, it supports insulin secretion in response to meals. In the stomach, it delays gastric emptying. In the brain (specifically areas including the hypothalamus and brainstem) it reduces the drive to eat. For a fuller look at the biological cascade, the page on how Wegovy works in the body covers each receptor site in more detail.

Over weeks and months, eating less consistently produces a calorie deficit, and body weight falls. The STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose alongside lifestyle support, a meaningful shift for most participants, not a marginal one. Fat mass drives most of the reduction, though some lean mass change is also observed, which is why maintaining adequate protein intake and resistance activity alongside treatment is worth discussing with your prescriber.

Physical changes you might notice, and some that may surprise you

The most commonly reported physical changes follow logically from the mechanisms above. Reduced appetite is almost universal among people who respond well. Feeling full sooner (sometimes after considerably less food than you'd expect) is a direct result of slowed gastric emptying. Some people describe food simply becoming less interesting, a shift in the reward value of eating that researchers attribute to semaglutide's action in the brain's mesolimbic system.

The gastrointestinal side effects that some people experience, particularly in the early weeks or after a dose increase, also trace back to those same mechanisms. Nausea, loose stools, constipation, indigestion and burping are the most common. For most people these settle as the body adjusts, but they can be significant at first. The body aches some people notice on Wegovy are a separate category, less well understood and worth reading about if that's a concern.

One change that sometimes catches people off guard is energy level. Some people feel fatigued, especially early in treatment. Some feel lighter and more mobile as weight falls. Headaches and dizziness are reported too, often linked to eating less and staying adequately hydrated. None of these should be dismissed as trivial, and none should be managed in isolation. That's what the aftercare support at a clinician-led service like ours exists for: questions don't stop after the prescription is written.

For questions about what these effects mean specifically for you, including how they might interact with other medicines or conditions, the detail sits in the full guide to what Wegovy does to your body.

What Wegovy is licensed to do, and the clinical context it requires

Wegovy holds a UK marketing authorisation for weight management in adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. It's used alongside a reduced-calorie diet and increased physical activity. NICE's appraisal (TA875) recommends it within specialist weight management services for a maximum of two years; the full NICE guidance on semaglutide sets out the eligibility criteria in detail.

Wegovy is not licensed for use during pregnancy, breastfeeding or if you are trying to conceive. It's also not licensed for anyone under 18. These aren't formalities. GLP-1 medicines cross into considerations that go well beyond appetite, and a prescriber's role is to map all of that before treatment starts.

Understanding Wegovy's full profile also means understanding cost. Private treatment prices vary, and a clear breakdown of what Wegovy costs privately in the UK is worth reading before you make any decisions. At nume, our prescribers review every consultation personally (not a questionnaire alone) and you can explore whether you might be suitable by starting a free consultation at any point.